WARNING
New Zealand law normally requires people who offer financial products to give information to investors before they invest. This requires those offering financial products to have disclosed information that is important for investors to make an informed decision.
The usual rules do not apply to this offer because there is an exclusion for offers to wholesale investors (this includes offers where the amount invested upfront by the investor, plus any other investments the investor has already made in the financial products, is $750,000 or more). As a result of this exclusion, you may not receive a complete and balanced set of information. You will also have fewer other legal protections for this investment.
If you are an accredited investor under the definition of that term in Rule 501(a) of Regulation D of the USSecurities Act of 1933, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.
Investments of this kind are not suitable for retail investors. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.
The opportunity exists for accredited investors as defined in Rule 501(a) of Regulation D of the US Securities Act of 1933, to express interest to invest in Aquyre Biosciences.
Aquyre Biosciences provides tissue adequacy assessment thru tissue micro-architecture delineation and intracellular data acquisition. The company's system provides a rapid on-site microscopic optical image of unstained surgical specimens immediately after resection, proprietary data used to create automated diagnosis algorithms, helping physicians to assist in forming a clinical judgment and rapidly and accurately identify cancer, immune and other cells. Its Full-Field Optical Coherence Tomography (FFOCT) offers en face (transverse), high resolution, 3D imaging of the tissue micro-architecture, at a resolution of 1μm. FFOCT also allows for depth exploration at different focal planes, without compromising 1μm resolution and is designed to capture data and present results in a few minutes from fresh live biopsies in the operating theatre. While the company's Dynamic Cell Imaging (DCI) enhances the cellular contrast by capturing the residual microscopic intracellular activity and behaviours in freshly excised tissue, without staining or partially destroying the tissue.
If you would like more information, click Register Interest below.
